600 Extra Days of Life: Johnson & Johnson's Heart Pump Shows Breakthrough Results in 10-Year Study

New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at…

ESC 2025 hears long-term data from DANGER-SHOCK trial - Cardiovascular News

Routine use of the Impella CP (Abiomed) micro-axial flow pump in the treatment of patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock leads to an absolute mortality reduction of 16.3% when compared to standard care at 10 years, long-term data from the DANGER-SHOCK trial have shown. These findings from the long-term follow up of patients in the investigator-initiated DanGer Shock randomised controlled…

600 Extra Days of Life: Johnson & Johnson's Heart Pump Shows Breakthrough Results in 10-Year Study

DanGer Shock trial data shows J&J's Impella CP reduces mortality by 16.3% over 10 years in heart attack patients with cardiogenic shock. Study of 360 patients published in NEJM.